STAGE IV ESOPHAGEAL CANCER AJCC V7
Clinical trials for STAGE IV ESOPHAGEAL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV ESOPHAGEAL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV ESOPHAGEAL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for tough esophageal cancer
Disease control OngoingThis study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with esophageal cancer that has spread. About 94 adults with metastatic esophageal or gastroesophageal junction cancer will receive either paclitaxel alone or paclitaxel plu…
Matched conditions: STAGE IV ESOPHAGEAL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:33 UTC
-
New drug combo aims to boost Radiation's punch against tough GI cancers
Symptom relief OngoingThis early-phase study tested an oral drug called ropidoxuridine (IPdR) in 19 people with advanced gastrointestinal cancers that could not be cured. The goal was to find the safest dose and see if the drug could make tumor cells more sensitive to radiation therapy. The study focu…
Matched conditions: STAGE IV ESOPHAGEAL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated May 17, 2026 05:34 UTC